RT Journal Article SR Electronic T1 Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.08.09.22278329 DO 10.1101/2022.08.09.22278329 A1 Karine Lacombe A1 Thomas Hueso A1 Raphael Porcher A1 Arsène Mekinian A1 Thibault Chiarabini A1 Sophie Georgin-Lavialle A1 Florence Ader A1 Julien Saison A1 Guillaume Martin Blondel A1 Nathalie De Castro A1 Fabrice Bonnet A1 Charles Cazanave A1 Anne François A1 Pascal Morel A1 Olivier Hermine A1 Valérie Pourcher A1 Marc Michel A1 Xavier Lescure A1 Nora Soussi A1 Philippe Brun A1 Fanny Pommeret A1 Pierre-Olivier Sellier A1 Stella Rousset A1 Lionel Piroth A1 Jean-Marie Michot A1 Gabriel Baron A1 Xavier De Lamballerie A1 Xavier Mariette A1 Pierre-Louis Tharaux A1 Matthieu Resche-Rigon A1 Philippe Ravaud A1 Tabassome Simon A1 Pierre Tiberghien YR 2022 UL http://medrxiv.org/content/early/2022/08/10/2022.08.09.22278329.abstract AB Background Efficacy of COVID-19 convalescent plasma (CCP) in COVID-19 pneumonia is uncertain. Early transfusion of high antibody titre CCP may be beneficial, especially in case of underlying immunodeficiency.Methods The CORIPLASM study was a multicentric, open-label, Bayesian randomised clinical trial evaluating the efficacy of CCP in patients with moderate COVID-19 pneumonia, including patients with underlying immunosuppression. Patients hospitalised with COVID-19 for less than 9 days were assigned to receive 2 plasma units/day over 2 days (CCP) or usual care (UC) alone. Primary outcomes were the proportion of patients with a WHO-Clinical Progression Score (CPS) ≥6 on the 10-point scale on day (d) 4 and survival without ventilation or additional immunomodulatory treatment by d14. Main analysis was conducted on the whole population and a planned subgroup analysis was performed according to immunosuppression status.Findings A total of 120 patients were recruited between April 16, 2020, and April 21, 2021, and assigned to CCP (n=60) or UC (n=60) with a 28 day-follow-up. The median time from symptoms onset to randomisation (days) was 7.0 [interquartile range (IQR) 5.0-9.0] and 7.0 [IQR 4.0-8.5] in CCP and UC, respectively. Thirteen (22%) patients with CCP had a WHO-CPS ≥6 at d4 versus 8 (13%) with UC, adjusted odds ratio (aOR) 1.88 [95% confidence interval (CI), 0.71 to 5.24]. By d14, 19 (31.6%) patients with CCP and 20 (33.3%) patients with UC had ventilation, additional immunomodulatory treatment or had died. Cumulative incidence of death was 3 (5%) with CCP and 8 (13%) with UC at d14 (aHR 0.40 [95%CI 0·10 -1·53]), and 7 (12%) with CCP and 12 (20%) with UC at d28 (aHR 0.51 [95% CI 0.20-1.32]). Subgroup analysis indicated that CCP might be associated with a lower mortality in patients with underlying immunosuppression (HR 0.37 [95% CI 0.14-0.97]). Serious adverse events were noted in 30 (50%) and 26 (43%) patients with CCP or UC, respectively.Interpretation CCP treatment did not improve early outcomes in patients with mild-to-moderate form COVID-19 pneumonia but was associated with reduced mortality in the subgroup of immunosuppressed patients.Trial registration clinicaltrials.gov Identifier: NCT04345991Funding Programme Hospitalier de Recherche Clinique / DGOS; Fondation pour la Recherche Médicale ; Sorbonne Université Paris; Emergency support instrument, DG Santé, European CommissionCompeting Interest StatementPT, PM and AF are employees of Etablissement Francais du Sang (EFS), the French public transfusion service, which collects, manufactures, tests and issues all blood components in France. All other co-authors declare no competing interests related to the topic of the study.Clinical TrialClinicaltrials.gov Identifier: NCT04345991Funding StatementProgramme Hospitalier de recherche Clinique (DGOS-French Ministry of Health), Fondation pour la Recherche Medicale, Sorbonne Universite AAP 2020, Emergency Support Instrument (ESI), DG Sante, European Commission. A CC-BY public copyright license (CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/) has been applied by the authors to the present document and will be applied to all subsequent versions up to the Author Accepted Manuscript arising from this submission, in accordance with the grant open access conditions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was obtained from Comite de Protection des Personnes (CPP) Ile de France VI on April 10, 2020 (no. 26-20 Med.1)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this article will be made available after publication on request from any qualified researchers or academicians. The data include: analysed deidentified participant data, data dictionary, study protocol, statistical analysis plan, and the informed consent form, among other data. The data will be shared for 2 years after publication upon receipt of a request sent to raphael.porcher{at}aphp.fr.